Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: rocket who wrote (14501)	2/9/1998 8:49:00 PM
From: Henry Niman	Respond to of 32384

Karl, I'm not sure about the burn rate. It's somewhat of a moving target because LGND keeps changing its source of income. ALRT provided about $40 million a year, but much of that was spent on in-house trials and this year most of the new trials will be those started by partners (which actually brings in money instead of burning it). Thus much of LGND's current income comes from partners in several programs, so the failure of any one is minimized. LGND expects to make money next year and they should have 4 different compounds (oral and topical Targretin and Panretin) on pharmacy shelves. In addition to the revenue from sales, they will have significant milestone payments from LLY (which initially just require the start of a diabetes trial in the US and an IND for a second generation rexinoid). I can look a little deeper and I'm expecting a copy of the Bear Stearns report (which predicts a profit next year) so it might be possible to tease out some of the details then.